Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Commentary|Articles|April 24, 2025
Oncology Experts Preview Top Abstracts From AUA 2025
Author(s)Caroline Seymour
Fact checked by: Chris Ryan
Experts highlight the top presentations to watch for at the 2025 AUA Annual Meeting.
Advertisement
Advertisement
Ahead of the
Related to this article
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Mark Garzotto, MD, discusses data with aglatimagene besadenovec plus valacyclovir and EBRT in intermediate- to high-risk localized prostate cancer.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement